Whole-Body Radioiodine Effective Half-Life in Patients with Differentiated Thyroid Cancer

Background: Radioactive (131)I (RAI) therapy is used in patients with differentiated thyroid cancer (DTC) after total thyroidectomy for remnant ablation, adjuvant treatment or treatment of persistent disease. (131)I retention data, which are used to indicate the time at which a (131)I treated DTC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Klain, Michele, Nappi, Carmela, De Risi, Marina, Piscopo, Leandra, Volpe, Fabio, Manganelli, Mariarosaria, Caiazzo, Elisa, Bianco, Davide, Schlumberger, Martin, Cuocolo, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535104/
https://www.ncbi.nlm.nih.gov/pubmed/34679438
http://dx.doi.org/10.3390/diagnostics11101740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535104/
https://www.ncbi.nlm.nih.gov/pubmed/34679438
http://dx.doi.org/10.3390/diagnostics11101740

Ejemplares similares